Drugs / AJU-C52L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06416865 | Jun → Dec 2022 | essential hypertension | AJU Pharm Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AJU-C52L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06416865 ↗ |